TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock News
NYSE:TEVA - New York Stock Exchange, Inc. - US8816242098 - ADR - Currency: USD
TEVA Latest News, Press Relases and Analysis
Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now
Short-term uncertainty has led to a golden opportunity for long-term investors.
Here's How You Should Play JNJ Stock After Q1 Earnings Beat
Those who own JNJ stock may stay invested for some time to see how the company achieves growth in 2025 amid the various challenges.
3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes
Despite the impact of dynamic shifts in the regulatory landscape for the Zacks Medical - Generic Drugs industry, new product launches should provide some respite to RDY, SDZNY and TEVA.
Mentions: RDY
5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility
Some of Wall Street's most-prominent asset managers were scooping up shares of time-tested businesses before the stock market meltdown.
Teva Pharmaceutical Industries (TEVA): Among the Top Healthcare Stocks to Buy According to Billionaire David Einhorn
We recently published a list of Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands against other top healthcare stocks to buy according to Billionaire David Einhorn. Wall Street has come down crashing on President […]
Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?
We recently published a list of Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn. In this article, we are going to take a look at where Coya Therapeutics, Inc. (NASDAQ:COYA) stands against other top healthcare stocks to buy according to Billionaire David Einhorn. Wall Street has come down crashing on President Donald […]
Is Gain Therapeutics (GANX) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?
We recently published a list of Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn. In this article, we are going to take a look at where Gain Therapeutics, Inc. (NASDAQ:GANX) stands against other top healthcare stocks to buy according to Billionaire David Einhorn. Wall Street has come down crashing on President Donald […]
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.
Is Plug Power Inc. (PLUG) the Best Hydrogen Stock to Buy According to Billionaires?
We recently published a list of 10 Best Hydrogen Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Plug Power Inc. (NASDAQ:PLUG) stands against other best hydrogen stocks to buy according to billionaires. As the global push toward clean energy and decarbonization gains momentum, hydrogen stocks […]
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
We came across a bullish thesis on Teva Pharmaceutical Industries Limited (TEVA) on Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical Industries Limited (TEVA)’s share was trading at $13.94 as of April 7th. TEVA’s trailing and forward P/E were 872 and 5.37 respectively according to Yahoo Finance. After years […]
Mentions: VZ
Jim Cramer Says Taiwan Semiconductor Manufacturing Company (TSM) Should “Do What NVIDIA Did” to Dodge Tariffs
We recently published a list of Jim Cramer Reveals Stocks Benefiting From Tariff Selloff & Discusses These 8 Stocks. In this article, we are going to take a look at where Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) stands against other stocks that Jim Cramer discusses. In his appearance on CNBC’s Squawk on the Street on […]
Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States
Teva and Samsung-Bioepis Launch Rare Disease Biosimilar in the U.S....
Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in...
Is Teva Pharmaceutical Industries (TEVA) the Most Undervalued Healthcare Stock to Buy According to Analysts?
We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA)stands against other most undervalued healthcare stocks to buy according to analysts. Rising Healthcare Costs and the Impact of Tariffs on US-China Trade […]
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
More than 92% of schizophrenia patients taking TEV-'749 in the SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule...
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press...
Teva Releases Q1 2025 Aide Memoire
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide...
Teva Releases Q1 2025 Aide Memoire
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March
TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis,...
Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March
2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals
The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical mental health services across 10...
2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals
The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical mental health services across 10 states
Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder
UZEDY is currently approved in the US as a subcutaneous long-acting injectable (LAI) for use every one or two months for the treatment of schizophrenia in...
Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder
Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease
Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with plans for a Phase 3 trial in 2025.
Mentions: SNY
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ...
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET
Mentions: SNY
Les besoins du patient au centre de toutes les priorités : pourquoi l’Europe doit agir pour protéger l’accès aux médicaments ?
AMSTERDAM, 21 févr. 2025 (GLOBE NEWSWIRE) -- Une nouvelle étude de Teva Pharmaceuticals Europe révèle que 46 % des médicaments génériques figurant...
Der Patient steht an erster Stelle: Warum Europa handeln muss, um den Zugang zu Arzneimitteln zu sichern
AMSTERDAM, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Laut einer neuen Studie von Teva Pharmaceuticals Europe werden 46 % der Generika auf der EU-Liste der...
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara® (ustekinumab)...